Physician profile
Danielle L Malin
NPI 1851688345
$9,538.42
in general payments reported to CMS, 2019-2025
35 companies · $907 in 2025
The $907 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $240 · 2021: $513 · 2022: $1,307 · 2023: $1,610 · 2024: $3,497 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Travel and Lodging: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.27 |
| Travel and Lodging | $2,406.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $2,953.48 | 2019-2025 | Novachor, Apligraf, Nushield |
| Convatec INC. | $1,888.40 | 2021-2025 | |
| Stryker Corporation | $1,688.60 | 2021-2025 | Inbone, Ortholoc 2 Lapifuse, Gravity Synchfix |
| Acell, INC. | $561.90 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $469.44 | 2019 | |
| Mimedx Group, INC. | $260.60 | 2025 | |
| Smith+Nephew, INC. | $198.51 | 2019-2025 | Collagenase Santyl, Regranex |
| Integra Lifesciences Corporation | $182.81 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Nevro Corp. | $168.64 | 2022 | |
| Abbvie INC. | $156.56 | 2021-2024 | |
| Allergan, INC. | $139.34 | 2019-2020 | |
| Lifenet Health | $104.70 | 2024-2025 | Theragenesis Wound Matrix |
| Paratek Pharmaceuticals, INC. | $94.89 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $79.17 | 2019 | |
| Treace Medical Concepts, INC. | $62.04 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $49.58 | 2020-2022 | |
| Triad Life Sciences INC. | $48.66 | 2022 | |
| Axogen | $37.27 | 2019 | |
| Kerecis Limited | $36.79 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Reapplix INC. | $34.38 | 2025 | 3c Patch Kit - Box |
| Kci USA, INC. | $34.18 | 2022-2023 | Activ.A.C. |
| Progenacare Global, LLC | $29.90 | 2023 | |
| Bioventus LLC | $29.48 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Nabriva Therapeutics, Plc | $29.19 | 2021 | |
| Music City Medical Technologies, LLC | $29.10 | 2025 | |
| Medtronic, INC. | $28.12 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.55 | 2021 | |
| Advanced Oxygen Therapy INC. | $20.64 | 2025 | Topical Oxygen Chamber For Extremities |
| Medartis INC. | $19.40 | 2020 | |
| Abbott Laboratories | $15.42 | 2023 | Eterna |
| Medtronic Vascular, INC. | $15.01 | 2020 | |
| Paragon 28, INC. | $14.48 | 2019 | |
| Depuy Synthes Sales INC. | $13.37 | 2021 | |
| Viiv Healthcare Company | $12.55 | 2019 | |
| Arteriocyte Medical Systems, INC. | $10.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Malin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.